<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128530</url>
  </required_header>
  <id_info>
    <org_study_id>32729463CSI2001</org_study_id>
    <nct_id>NCT01128530</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)</brief_title>
  <official_title>A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Furiex Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Furiex Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical efficacy, safety, and tolerability of
      a 250 mg BID oral dose of JNJ-32729463 compared with linezolid in subjects with complicated
      skin and skin structure infections (cSSSIs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cessation of spread or reduction in the size of the primary infection site lesion</measure>
    <time_frame>48-72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Defervescence</measure>
    <time_frame>48 - 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of signs and symptoms of the primary infection site lesion</measure>
    <time_frame>up to day 84-98 (late follow-up visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate - overall and for MRSA</measure>
    <time_frame>Day 10 (TOC visit), Day 15-21 (SFU/EOT visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological response rate - overall and for MRSA</measure>
    <time_frame>Day 15-21 (SFU/EOT visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in susceptibility testing of S. aureus</measure>
    <time_frame>Day 15-21 (SFU/EOT visit)</time_frame>
    <description>Changes in susceptibility testing of S. aureus isolates from the original infection site to linezolid and JNJ-32729463</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence and new infection in subjects with MRSA</measure>
    <time_frame>Day 35-49 and Day 84-98</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defervescence</measure>
    <time_frame>Day 4 (Visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cessation of spread or reduction in the size of the primary infection site lesion</measure>
    <time_frame>Day 4 (Visit 3)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Complicated Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>JNJ-32729463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>linezolid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-32729463</intervention_name>
    <description>250 mg tablet twice daily</description>
    <arm_group_label>JNJ-32729463</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid</intervention_name>
    <description>600 mg tablet twice daily</description>
    <arm_group_label>linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-32729463 placebo</intervention_name>
    <description>1 placebo tablet twice daily</description>
    <arm_group_label>linezolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linezolid placebo</intervention_name>
    <description>1 placebo tablet, twice daily</description>
    <arm_group_label>JNJ-32729463</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of a complicated skin and skin structure infection (cSSSI)
             including wound infection, deep cellulitis or severe abscess

          -  Women of childbearing potential must agree to use an acceptable form of contraception

          -  Infection site offers ability to obtain a microbiological specimen

          -  Received only 1 dose of any potentially effective systemic antibiotic within 24 hours
             of beginning study treatment

        Exclusion Criteria:

          -  History of hypersensitivity or allergic reaction to quinolones or to linezolid

          -  Female and pregnant or breastfeeding or may be pregnant

          -  Chronic or underlying skin condition surrounding the area of infection that may
             complicate the assessment of response (e.g. atopic dermatitis, eczema, or psoriasis)

          -  Subject has infections with a high cure rate after surgical incision alone after
             aggressive local skin care

          -  Subject has infection(s) suspected to be caused by Gram-negative rods, anaerobic
             bacteria or unusual pathogens

          -  Subject has an infection that is expected to require other antifungal,
             antimycobacterial, or antibacterial agents in addition to study medication

        Other protocol-specific eligibility criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <zip>34769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sulphur</city>
        <state>Louisiana</state>
        <zip>70663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Keego Harbor</city>
        <state>Michigan</state>
        <zip>48320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aac.asm.org/content/55/12/5790.full</url>
    <description>Journal article reporting results of the Phase 2 study</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <disposition_first_submitted>January 25, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 25, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 1, 2011</disposition_first_posted>
  <last_update_submitted>December 9, 2011</last_update_submitted>
  <last_update_submitted_qc>December 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>June Almenoff, MD, President/CMO</name_title>
    <organization>Furiex Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>cSSSI</keyword>
  <keyword>complicated skin and skin structure infections</keyword>
  <keyword>acute bacterial skin and skin structure infections</keyword>
  <keyword>abscess</keyword>
  <keyword>cellulitis</keyword>
  <keyword>bacterial infections</keyword>
  <keyword>anti-bacterial agents</keyword>
  <keyword>anti-infective agents</keyword>
  <keyword>skin diseases, infectious</keyword>
  <keyword>skin diseases</keyword>
  <keyword>wound infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

